Satoru Konnai

This inventor holds 5 USPTO granted patents and 5 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: Fuso Pharmaceutical Industries, Ltd., Hokkaido University. Active years: 2020-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Satoru Konnai. Retrieved from https://idiyas.com/inventor/satoru-konnai

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5 (Patent Applications = 5)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 5)

EPO Patents = 1 (Patent Applications = 6)

Average Co-Inventor Count = 9.4

ph-index = 1

Forward Citations = 1(Granted Patents)

Company Filing History:

5 out of 108

Fuso Pharmaceutical Industries, Ltd.

where one patent can have more than one assignee

Years Active: 2020-2023

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11781146 - Vector including a translation-impaired dihydrofolate reductase gene cassette and ubiquitously acting chromatin opening element (2023-10-10),

2. 11697686 - Anti-PD-L1 antibody for detecting PD-L1 (2023-07-11),

3. 11312773 - Anti-PD-L1 antibody (2022-04-26),

4. 11198730 - Anti-LAG-3 antibody (2021-12-14),

5. 10865246 - Anti-PD-L1 antibody for detecting PD-L1 (2020-12-15),

Title: Satoru Konnai: Innovator in Genetic Engineering

Introduction

Satoru Konnai is a prominent inventor based in Hokkaido, Japan. He has made significant contributions to the field of genetic engineering, holding a total of 5 patents. His work focuses on developing innovative solutions for protein production and cancer detection.

Latest Patents

Konnai's latest patents include a vector that incorporates a translation-impaired dihydrofolate reductase gene cassette. This invention provides mammalian cell expression vectors that enable host cells to produce high levels of foreign gene-derived proteins. Additionally, he has developed an anti-PD-L1 antibody capable of staining tumor cells, such as melanoma cells. This antibody comprises specific amino acid sequences that enhance its effectiveness in detecting PD-L1, along with a method for its preparation.

Career Highlights

Throughout his career, Satoru Konnai has worked with esteemed institutions, including Hokkaido University and Fuso Pharmaceutical Industries, Ltd. His research has significantly advanced the understanding of gene expression and cancer biology.

Collaborations

Konnai has collaborated with notable colleagues, including Tomohiro Okagawa and Kazuhiko Ohashi. Their joint efforts have contributed to the success of various research projects and innovations in the field.

Conclusion

Satoru Konnai's contributions to genetic engineering and cancer research highlight his role as an influential inventor. His innovative patents and collaborations continue to impact the scientific community positively.

Profile summary based on public USPTO records.